Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naive Japanese patients with diabetes

Diabetes Technology and Therapeutics

Volumn 9, Issue 3, 2007, Pages 246-253

  Tamemoto, Hiroyuki ^a   Ikoma, Aki ^a   Saitoh, Takako ^a   Ishikawa, San E ^a   Kawakami, Masanobu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEVICE; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; JAPAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 34250733457     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.0016     Document Type: Article

References (20)

1. Yki-Järvinen H: Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24:758-767.
2. Riddle MC: Timely addition of insulin to oral therapy for type 2 diabetes. Diabetes Care 2002;25:395-396.
3. Wright A, Felix Burden AC, Paisey RB, Cull CA, Holman RR; for the U.K. Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-336.
4. Riddle MC, Schneider J; for the Glimepride Combination Group: Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepride versus insulin alone. Diabetes Care 1998;21:1052-1057.
5. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; for the INITIATE Study Group: Initiating insulin therapy in type 2 diabetes, a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-265.
6. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H: Comparison of basal insulin added to oral agents versus twice-daily pre-mixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-259.
7. Roach P, Malone JK: Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with type 2 diabetes. Diabet Med 2006;23:743-749.
8. Eliaschewitz FG, Calvo C, albuena H, Ruiz M, Aschner P, Villena J, Ramirez LA, Jimenez J; for the HOE901/4013 LA Study Group: Therapy in type 2 diabetes: insulin glargine vs. NPH inulin both in combination with glimepiride. Arch Med Res 2006;37:495-501.
9. Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, Tulokas T, Hulme S, Hardy k, McNulty S, Hamminene J, Levanen H, Lajdenpera S, Lehtonen R, Ryysy L: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451.
10. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G: Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006;29:554-559.
11. Kelley DE, Bidot P, Freedman Z, Haag B, Poddlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J: Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998;21:2056-2061.
12. Furlong N, Hulme SA, O'Brien SV, Hardy KJ: Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 2002;25:1685-1690.
13. De Luis DA, Aller R, Cuellar L, Terroba C, Ovalle O, Izaola O, Romero E: Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:1844-1845.
14. Strowig SM, Avilez-Santa ML, Raskin P: Comparison of insulin monotherapy and combination therapy with insulin and metformin therapy or insulin and troglitazone in type 2 diabetes. Diabetes Care 2002;25:1691-1697.
15. Wulffele MG, Kooy A, Lehert P, Bets D, Ogterop JC, van Der Burg BB, Donker ABJM, Stehouwer CDA: Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002;25:2133-2140.
16. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J; for the Rosiglitazone Clinical Trial Study Group: A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-1232.
17. Ose H, Fukui M, Kitagawa Y, Hirata C, Ichio N, Kadono M, Mogami S, Onishi M, Ichida Y, Nakajima T, Hasegawa G, Yoshikawa T, Nakamura N: Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus. Endocr J 2005;52:563-569.
18. Bretzel RG, Linn T; for the Apollo Study Group: Equivalence of basal insulin glargine vs prandial insulin lispro for glucose control in type 2 diabetes patients on oral agents - results of the APOLLO study. Poster 326-P presented at the American Diabetes Association Annual Scientific Meeting, Washington, DC, 2006.
19. Jacober SJ, Scism-Bacon JL, Zagar AJ; for the IONW Study Investigators'. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006;8:448-455.
20. Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S: Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Curr Med Res Opin 2005;21:2063-2071.